| Dr John King, MD | |
|
9800 Baptist Health Dr Ste 200, Little Rock, AR 72205-6243 | |
| (501) 219-0900 | |
| (501) 312-4750 |
| Full Name | Dr John King |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 24 Years |
| Location | 9800 Baptist Health Dr Ste 200, Little Rock, Arkansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255350021 | NPI | - | NPPES |
| 205037001 | Medicaid | AR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207WX0107X | Ophthalmology - Retina Specialist | E8699 (Arkansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baptist Health Medical Center-little Rock | Little rock, AR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Retina Associates, P.a. | 3375510126 | 6 |
News Archive
When Presidential candidate Hillary Clinton spoke to a packed auditorium full of medical students and doctors at George Washington University, she proposed a new health care plan.
Lonza Houston, Inc., a global leader in biological, cell and viral gene therapy manufacturing, and Benitec Biopharma, a clinical stage biotechnology company commercializing a patented gene-silencing technology, DNA-directed RNA interference (ddRNAi), today announced that they have entered into a Manufacturing Services Agreement to develop a scalable manufacturing process for Benitec's ddRNAi-based, Adeno-Associated Virus (AAV)-delivered products intended for therapeutic use in humans.
ZIOPHARM Oncology, Inc. announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for Application Serial No. 11/257,766 entitled "Salts of Isophosphoramide mustard and analogs thereof as anti-tumor agents" with claims directed to compounds, pharmaceutical compositions, and lyophilisates. These claims cover the Company's proprietary palifosfamide composition (ZIO-201 or ZymafosTM). The Company has recently reported positive randomized Phase II sarcoma interim data for intravenous palifosfamide at the Annual Meeting of the Connective Tissue Oncology Society (CTOS) on November 6, 2009 and expects, following U.S. Food and Drug Administration (FDA) review, to initiate a registration trial the first half of 2010.
The dermatological impact of COVID-19 is a burning topic at EADV's 2021 Spring Symposium. New research presented today highlights the effect that stringent hand hygiene during the pandemic has had on hand skin health.
An increasing number of hospitals across the U.S. in an effort to promote breast-feeding are banning free gift bags that contain samples of infant formula, which often are given to women when they leave the hospital after delivery, the Wall Street Journal reports.
› Verified 8 days ago
| Entity Name | Retina Associates, P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447215603 PECOS PAC ID: 3375510126 Enrollment ID: O20040913000483 |
News Archive
When Presidential candidate Hillary Clinton spoke to a packed auditorium full of medical students and doctors at George Washington University, she proposed a new health care plan.
Lonza Houston, Inc., a global leader in biological, cell and viral gene therapy manufacturing, and Benitec Biopharma, a clinical stage biotechnology company commercializing a patented gene-silencing technology, DNA-directed RNA interference (ddRNAi), today announced that they have entered into a Manufacturing Services Agreement to develop a scalable manufacturing process for Benitec's ddRNAi-based, Adeno-Associated Virus (AAV)-delivered products intended for therapeutic use in humans.
ZIOPHARM Oncology, Inc. announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for Application Serial No. 11/257,766 entitled "Salts of Isophosphoramide mustard and analogs thereof as anti-tumor agents" with claims directed to compounds, pharmaceutical compositions, and lyophilisates. These claims cover the Company's proprietary palifosfamide composition (ZIO-201 or ZymafosTM). The Company has recently reported positive randomized Phase II sarcoma interim data for intravenous palifosfamide at the Annual Meeting of the Connective Tissue Oncology Society (CTOS) on November 6, 2009 and expects, following U.S. Food and Drug Administration (FDA) review, to initiate a registration trial the first half of 2010.
The dermatological impact of COVID-19 is a burning topic at EADV's 2021 Spring Symposium. New research presented today highlights the effect that stringent hand hygiene during the pandemic has had on hand skin health.
An increasing number of hospitals across the U.S. in an effort to promote breast-feeding are banning free gift bags that contain samples of infant formula, which often are given to women when they leave the hospital after delivery, the Wall Street Journal reports.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr John King, MD 9800 Baptist Health Dr Ste 200, Little Rock, AR 72205-6243 Ph: (501) 219-0900 | Dr John King, MD 9800 Baptist Health Dr Ste 200, Little Rock, AR 72205-6243 Ph: (501) 219-0900 |
News Archive
When Presidential candidate Hillary Clinton spoke to a packed auditorium full of medical students and doctors at George Washington University, she proposed a new health care plan.
Lonza Houston, Inc., a global leader in biological, cell and viral gene therapy manufacturing, and Benitec Biopharma, a clinical stage biotechnology company commercializing a patented gene-silencing technology, DNA-directed RNA interference (ddRNAi), today announced that they have entered into a Manufacturing Services Agreement to develop a scalable manufacturing process for Benitec's ddRNAi-based, Adeno-Associated Virus (AAV)-delivered products intended for therapeutic use in humans.
ZIOPHARM Oncology, Inc. announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for Application Serial No. 11/257,766 entitled "Salts of Isophosphoramide mustard and analogs thereof as anti-tumor agents" with claims directed to compounds, pharmaceutical compositions, and lyophilisates. These claims cover the Company's proprietary palifosfamide composition (ZIO-201 or ZymafosTM). The Company has recently reported positive randomized Phase II sarcoma interim data for intravenous palifosfamide at the Annual Meeting of the Connective Tissue Oncology Society (CTOS) on November 6, 2009 and expects, following U.S. Food and Drug Administration (FDA) review, to initiate a registration trial the first half of 2010.
The dermatological impact of COVID-19 is a burning topic at EADV's 2021 Spring Symposium. New research presented today highlights the effect that stringent hand hygiene during the pandemic has had on hand skin health.
An increasing number of hospitals across the U.S. in an effort to promote breast-feeding are banning free gift bags that contain samples of infant formula, which often are given to women when they leave the hospital after delivery, the Wall Street Journal reports.
› Verified 8 days ago
Robert Lowery, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 4301 W Markham St # 783, Little Rock, AR 72205 Phone: 501-686-8000 | |
Lydia F Lane, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 9800 Lile Dr, Suite 400, Little Rock, AR 72205 Phone: 501-224-5658 Fax: 501-224-8114 | |
Dr. David R Rozas, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 5300 W. Markham, Little Rock, AR 72205 Phone: 501-664-5354 Fax: 501-664-5257 | |
Ammar N Safar, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 4301 W Markham St, 523, Little Rock, AR 72205 Phone: 501-686-5150 Fax: 501-526-6562 | |
Dr. Jennifer Anderson, MD Ophthalmology Medicare: Medicare Enrolled Practice Location: 4301 W Markham St # 783, Little Rock, AR 72205 Phone: 501-686-8000 | |
Monica Verma, MD Ophthalmology Medicare: Medicare Enrolled Practice Location: 11825 Hinson Rd Ste 103, Little Rock, AR 72212 Phone: 501-747-1625 Fax: 501-747-1626 | |
Dr. Tom Kornhauser, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 4301 W Markham St # 523, Little Rock, AR 72205 Phone: 501-686-5852 Fax: 501-686-8560 |